Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.38 |
| ▸ | BUB1 | O43683 | 4/20 | 0.34 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762768 | 0.85 | NAMPT (0.41) | EHMT2BUB1HTR2CDGAT1TP53 | |
| SCHEMBL6764234 | 0.84 | MAPT (0.39) | BUB1TP53MAPT | |
| SCHEMBL6302615 | 0.83 | HTR2C (0.36) | EHMT2BUB1HTR2C | |
| SCHEMBL6762807 | 0.82 | KDR (0.38) | BUB1 | |
| SCHEMBL6092473 | 0.80 | EHMT2 (0.38) | EHMT2HTR2C | |
| SCHEMBL8251851 | 0.80 | HTR2C (0.43) | BUB1HTR2C | |
| SCHEMBL6094319 | 0.78 | HTR2C (0.40) | BUB1HTR2CMAPT | |
| SCHEMBL6094099 | 0.77 | HTR2C (0.39) | EHMT2BUB1HTR2C | |
| SCHEMBL8584124 | 0.77 | KMT2A (0.45) | HTR2CMAPTMEN1POLBKMT2A | |
| SCHEMBL6093576 | 0.76 | HTR2C (0.38) | EHMT2BUB1HTR2CMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | claimed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220253-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | EHMT2 2778/4885BUB1 2569/4885HTR2C 779/4885 |
| US-20020151718-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | EHMT2 2778/4885BUB1 2569/4885HTR2C 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.